Ascendis Pharma exec exercises, sells 3K shares

Ascendis Pharma A/S (ASND) reports that SVP & PAO Mads Bodenhoff exercised warrants for 3,000 Ordinary Shares on September 8, 2026 at an exercise price of $110.00 per share and on the same date sold 3,000 Ordinary Shares at $270.19 per share.

Rhea-AI Filing Summary

Ascendis Pharma A/S (ASND) reports that SVP & PAO Mads Bodenhoff exercised warrants for 3,000 Ordinary Shares on September 8, 2026 at an exercise price of $110.00 per share and on the same date sold 3,000 Ordinary Shares at $270.19 per share. Following the exercise, 687 warrants remain outstanding, expiring on October 11, 2032, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Exercise and Sale: 3,000 shares ($481K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Bodenhoff Mads

Role SVP & PAO

Sold 3,000 shs ($811K)

Approx. gross sale proceeds $811K

Approx. exercise cost $330K

Approx. pre-tax spread $481K

Type	Security	Shares	Price	Value
Exercise	Warrants F1	3,000	$0.00	$0.00
Exercise	Ordinary Shares	3,000	$110.00	$330K
Sale	Ordinary Shares	3,000	$270.19	$811K

Holdings After Transaction: Warrants — 687 contracts (Direct); Ordinary Shares — 0 shares (Direct)

Footnotes (1)

1. F1. The warrants vested 25% on October 11, 2023 and thereafter in 36 equal monthly installments.

Key Figures

Warrants exercised: 3,000 warrants Exercise price: $110.00 per share Shares sold: 3,000 shares +5 more

8 metrics

Warrants exercised 3,000 warrants Exercised into Ordinary Shares on September 8, 2026

Exercise price $110.00 per share Exercise price of warrants converted into 3,000 Ordinary Shares

Shares sold 3,000 shares Ordinary Shares sold on September 8, 2026

Sale price $270.19 per share Price for 3,000 Ordinary Shares sold on September 8, 2026

Warrants remaining 687 warrants Total warrants held directly after the reported exercise

Warrant expiration date October 11, 2032 Expiration of remaining warrants held by the reporting person

Initial vesting tranche 25% Warrants vested 25% on October 11, 2023 before monthly installments

Vesting installments 36 monthly installments Remaining vesting schedule after the initial 25% vesting

Key Terms

warrants, derivative security, Rule 10b5-1

3 terms

warrants financial

"The warrants vested 25% on October 11, 2023 and thereafter in 36 equal"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

derivative security financial

"Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Rule 10b5-1 regulatory

"no Rule 10b5-1 trading plan is reported for these transactions"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transactions did ASND executive Mads Bodenhoff report on September 8, 2026?

Bodenhoff exercised 3,000 warrants for Ascendis Pharma A/S Ordinary Shares at an exercise price of $110.00 per share and then sold 3,000 Ordinary Shares at $270.19 per share on September 8, 2026.

What was the exercise price of the warrants in the ASND Form 4?

The warrants reported by the Ascendis Pharma A/S SVP & PAO had an exercise price of $110.00 per share, and they were exercised for 3,000 Ordinary Shares on September 8, 2026.

At what price were Ascendis Pharma (ASND) shares sold in this Form 4?

The Form 4 reports that 3,000 Ascendis Pharma Ordinary Shares were sold at a price of $270.19 per share on September 8, 2026, following the exercise of warrants into the same number of shares.

How many warrants does the ASND executive hold after these transactions?

After exercising 3,000 warrants, the Ascendis Pharma SVP & PAO holds 687 warrants directly. These remaining warrants are reported with an expiration date of October 11, 2032.

Were the ASND insider transactions made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported for these transactions by the Ascendis Pharma A/S SVP & PAO.

What does the footnote say about the vesting of the ASND warrants?

The footnote states that the warrants vested 25% on October 11, 2023 and then vested in 36 equal monthly installments thereafter, describing the vesting schedule for the derivative security that was exercised.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 05:04 PM Accepted by SEC EDGAR 09/09/2026 - 05:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bodenhoff Mads

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

DENMARK

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & PAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/08/2026		M		3,000	A	$110	3,000	D
Ordinary Shares	09/08/2026		S		3,000	D	$270.19	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$110	09/08/2026		M			3,000	(1)	10/11/2032	Ordinary Shares	3,000	$0	687	D

Explanation of Responses:

1. The warrants vested 25% on October 11, 2023 and thereafter in 36 equal monthly installments.

	/s/ Michael Wolff Jensen as attorney-in-fact for Mads Bodenhoff	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)